Human Immunodeficiency Virus (Hiv) Attacks The Body's Immune System, Making The Host System Susceptible To Infection, And Thus Leading To Complete Damage. The Virus Attacks The Cd4 Cells, Which Help The Immune System Defend Infections. The Major Route Of Transmission Of Hiv Infection Is Through Unprotected Sex, Use Of Contaminated Needle, Breast Milk Of The Hiv Infected Mother, And Infected Blood.
The Global Hiv Drugs Market Was Valued At $20,448 Million In 2015, And Is Estimated To Reach $26,458 Million By 2022, Growing At A Cagr Of 3.7% During The Forecast Period From 2016 To 2022. The Major Factors That Boost The Growth Of The Market Include Increase In Prevalence Of Hiv Globally And Rise In Treatment & Diagnosis Rate. Moreover, Growth In Awareness About The Treatment Options & Care With The Various Initiatives And Education Campaigns Introduced By Government Agencies Across The Globe Plays An Important Role In The Growth Of Hiv Drugs Market. However, Stringent Government Regulations For The Approval And Commercialization Of Hiv Drugs Is Expected To Restrain The Growth Of The Hiv Drugs Market.
The Report Segments The Market Based On Medication Class And Geography. On The Basis Of Medication Class, The Market Is Divided Into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Protease Inhibitors (Pis), Fusion Inhibitors (Fi), Entry Inhibitors, Hiv Integrase Stand Transfer Inhibitors. Based On Geography, The Market Is Analyzed Across North America, Europe, Asia-Pacific, And Lamea. The North American Region Accounted For Around Half Of The Share In The Overall Hiv Drug Market In 2015, And Is Expected To Maintain This Lead Throughout The Forecast Period. The Growth In The Hiv Drug Market In The Region Is Attributed To Well-Established Healthcare System, Higher Diagnosis & Treatment Rate In The Region, And Development And Increase In The Adoption Of Advanced Treatment Options From The Hiv Infected Population.
Key Benefits for Stakeholders
The Study Provides An In-Depth Analysis Of The Hiv Drugs Market, With Current Trends And Future Estimations To Elucidate The Imminent Investment Pockets.
It Presents A Quantitative Analysis From 2014 To 2022 To Enable The Stakeholders To Capitalize On Prevailing Market Opportunities.
Extensive Analysis Of The Hiv Drug Market, By Medication Class, Assists In The Effective Treatment Of Hiv/Aids.
Key Players Are Profiled And Their Strategies Are Analyzed Thoroughly, Which Predicts The Competitive Outlook Of The Market.
HIV Drug Market Key Segments
By Medication Class
Multi-Class Combination Drugs
Atripla
Complera
Prezcobix/Prezista
Stribild
Triumeq
Nucleoside Reverse Transcriptase Inhibitors (Nrtis)
Combivir
Emtriva
Epivir
Epzicom
Trizivir
Truvada
Viread
Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)
Edurant
Intelence
Rescriptor
Sustiva
Viramune (Immediate Release)
Protease Inhibitors (Pis)
Aptivus
Crixivan
Kaletra
Lexiva
Norvir
Reyataz
Viracept
Fusion Inhibitors(Fi)
Fuzeon
Entry Inhibitors
Selzentry
Hiv Integrase Stand Transfer Inhibitors
Isentress
Tivicay
By Geography
North America
Europe
Asia-Pacific
Lamea
List Of Key Players Profiled in the Report
Boehringer Ingelheim International Gmbh
Merck & Co.
Bristol-Myers Squibb
Gilead Sciences Inc.
Viiv Healthcare
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Abbvie
Cipla Limited
List Of Other Players in the Value Chain
(These Players Are Not Profiled In The Report. The Same Will Be Included On Request)
Daiichi Sankyo
Emcure
Hetero Drugs
Mylan
Astrazeneca
